INmune Bio, Inc. (NASDAQ:INMB) Sees Large Increase in Short Interest

INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) saw a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 4,280,000 shares, a growth of 7.0% from the December 31st total of 4,000,000 shares. Based on an average daily volume of 229,900 shares, the short-interest ratio is currently 18.6 days.

INmune Bio Price Performance

NASDAQ:INMB traded down $0.20 during mid-day trading on Friday, reaching $9.60. The stock had a trading volume of 273,448 shares, compared to its average volume of 494,586. The stock has a market cap of $212.83 million, a P/E ratio of -4.40 and a beta of 1.86. The business's 50 day moving average is $6.13 and its 200 day moving average is $6.11. INmune Bio has a fifty-two week low of $4.32 and a fifty-two week high of $14.74.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Alliance Global Partners started coverage on shares of INmune Bio in a report on Monday, October 21st. They set a "buy" rating and a $20.00 price target for the company. RODMAN&RENSHAW raised shares of INmune Bio to a "strong-buy" rating in a research note on Tuesday, January 28th. Finally, Rodman & Renshaw started coverage on shares of INmune Bio in a research note on Tuesday, January 28th. They issued a "buy" rating and a $23.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $20.75.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Financial Advocates Investment Management boosted its holdings in INmune Bio by 17.4% in the third quarter. Financial Advocates Investment Management now owns 13,500 shares of the company's stock worth $73,000 after purchasing an additional 2,000 shares in the last quarter. Rhumbline Advisers lifted its position in shares of INmune Bio by 16.9% in the fourth quarter. Rhumbline Advisers now owns 16,744 shares of the company's stock worth $78,000 after buying an additional 2,424 shares during the last quarter. Fermata Advisors LLC lifted its position in shares of INmune Bio by 10.0% in the fourth quarter. Fermata Advisors LLC now owns 46,997 shares of the company's stock worth $219,000 after buying an additional 4,267 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of INmune Bio during the 3rd quarter worth about $79,000. Finally, Westside Investment Management Inc. increased its holdings in shares of INmune Bio by 26.2% during the 4th quarter. Westside Investment Management Inc. now owns 89,975 shares of the company's stock valued at $420,000 after acquiring an additional 18,660 shares during the last quarter. Institutional investors and hedge funds own 12.72% of the company's stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.